Top

Published in:

01-08-2007 | Breast

Validation and Limitations of Use of a Breast Cancer Nomogram Predicting the Likelihood of Non–Sentinel Node Involvement After Positive Sentinel Node Biopsy

Authors: Séverine Alran, MD, Yann De Rycke, PhD, Virginie Fourchotte, MD, Hélène Charitansky, MD, Fatima Laki, MD, Marie Christine Falcou, DM, Myriam Benamor, MD, Paul Freneaux, MD, Rémy Jacques Salmon, MD, Brigitte Sigal-Zafrani, MD, for the Institut Curie Breast Cancer Study Group

Published in: Annals of Surgical Oncology | Issue 8/2007

Abstract

Background

Axillary lymph node dissection (ALND) for patients with positive sentinel lymph nodes (SLNs) is currently under discussion in the literature. The breast cancer nomogram (BCN), an online tool developed by the Memorial Sloan-Kettering Cancer Center (MSKCC), aims to predict the risk of positive non-SLN in SLN-positive patients. The purpose of this study was to test the accuracy of the nomogram on patients with macrometastatic and micrometastatic SLN-positive biopsy findings.

Methods

Patient characteristics, tumor pathology, and positive SLN characteristics were collected on 588 consecutive patients who underwent completion ALND. The MSKCC BCN tool was used to calculate risk of metastases for all 588 cases that included a subgroup of the 213 patients with SLN micrometastases. The BCN was performed for positive SLN biopsy findings regardless of the method of metastasis detection. Evaluation of the BCN was performed by the area under the curve method.

Results

The BCN applied to all 588 patients achieved an area under the receiver operating characteristic curve (ROC) of .724 (range, .677–.771) compared with .76 in the MSKCC study. When the tool was applied solely to micrometastases found by hematoxylin and eosin staining and metastases found by immunohistochemistry, the area under the ROC was .538 (range, .423–.653).

Conclusions

The MSKCC nomogram has been validated for all the patients having a metastatic SLN at the Institut Curie. However, this model was not reliably predictive for positive non–SLN in cases with micrometastic positive SLN.

Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993; 2:335–40PubMedCrossRef

Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994; 200:391–8CrossRef

Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenctomy in breast cancer. J Clin Oncol 1997; 15:2345–50PubMed

Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel lymph node biopsy in the patient with breast cancer. JAMA 1996; 276:1818–22PubMedCrossRef

Veronesi U, Paganelli G, Galimberti V, et al. Sentinelnode biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997; 349:1864–7PubMedCrossRef

O’Hea BJ, Hill AD, El Shirbiny Am, et al. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg 1998; 186:423–7PubMedCrossRef

Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer: a multicenter validation study. N Engl J Med 1998; 339:941–6PubMedCrossRef

Veronesi U, Paganelli G, Viale G, et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst 1999; 91:368–73PubMedCrossRef

Cady B. Guest Editorial, case against axillary lymphadenectomy for most patients with infiltrating breast cancer. J surg Oncol 1997; 66:7–10PubMedCrossRef

10.

Nos C, Harding C, Freneaux P, Trie A, Falcou MC, Sastres-Garau X, Clough KB. Predicting of tumour in remaining axillary lymph nodes when the sentinel node in a woman with breast cancer contains metastases. Br J Surg 2003; 90;11:1354–60

11.

Julian TB, Anderson S, Krag D, et al. Continued technical results of NSABP B-32: does a positive sentinel node biopsy require an axillary dissection? Breast Cancer Res Treat 2005; 94:S20

12.

Degnim AC, Kriffith KA, Newman L. Clinicopathologic features of metastasis in non sentinel lymph nodes of breast carcinoma patients: a metaanalysis. Cancer 2003; 98:2307–15PubMedCrossRef

13.

Van Zee KJ, Manasseh D, Bevilacqua J, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel lymph node biopsy. Ann Surg Oncol 2003; 10:1140–51PubMedCrossRef

14.

Nos C, Freneaux P, Guilbert S, Falcou MC, Salmon RJ, Clough KB. Sentinel lymph node detection for breast cancer: which patients are best suited for the patent blue dye only method of identification? Ann Surg Oncol 2001; 8:438–43PubMedCrossRef

15.

Salmon RJ, Nos C, Lojodice F, et al. Sentinel node and operable breast cancer: utilization of blue dye injection: pilot study. Ann Chir 2000; 125:253–8PubMedCrossRef

16.

Freneaux P, Nos C, Vincent-Salomon A, et al. Histological detection of minimal metastatic involvement in axillary sentinel nodes: a rational basis for a sensitive methodology usable in daily practice. Mod Pathol 2002; 15:641–6PubMedCrossRef

17.

Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39:561–77PubMed

18.

Metz CE. ROC methodology in radiologic imaging. Invest Radiol 1986; 21:720–33PubMedCrossRef

19.

Hanley JA, McNeil BJ: The meaning of the area under the receiver operating characteristic (ROC) curve. Radiology 1982; 143:29–36PubMed

20.

Lambert L, Hunt KK, Hwang RF, Meric-Bernstam F, et al. Validation of a breast cancer nomogram for predicting additional nodal metastases after positive sentinel node biopsy. Ann Surg Oncol 2005; 12(Suppl):S17

21.

Degnim A, Reynolds C, Newman LA, et al. Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. Am J Surg 2005; 190:543–50PubMedCrossRef

22.

Soni NK, Carmalt HL, Gillette DJ, Spillane AJ. Evaluation of a breast cancer nomogram for prediction of non-sentinel lymph node positivity. Eur J Sur Oncol 2005; 31(9):958–64CrossRef

23.

Kocsis L, Svebis M, Cserni G, et al. Use and limitations of a nomogram predicting the likelihood of non-sentinel node involvement after a positive sentinel node biopsy in breast cancer patients. Am Surg 2004; 70:1019–24PubMed

24.

Smidt ML, Kuster M, Strobbe LJA, et al. Can the Memorial Sloan-Hettering Cancer Center nomogram predict the like lihood of sentinel lymph node metastases in breast cancer patients in the Netherlands? Ann Surg Oncol 12:1066–72

25.

Viale G, Maiorano E, Mazzarol G, et al. Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Ann Surg 2005; 241:319–25PubMedCrossRef

26.

Dowlatshahi K, Fan M, Snider H, Habib F. Lymph node micrometastases from breast carcinoma. Cancer 1997; 80:1188–97PubMedCrossRef

27.

Chapgar A, Middleton LP, Hunt KK, et al. Clinical outcome of patients with lymph node–negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer 2005; 103:1581–6CrossRef

28.

Langer I, Marti R, Zuber M, et al. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node or SLN micrometastases. Ann Surg 2005; 241:152–8PubMed

29.

Fournier K, Schiller A, Perry R, Laronga C. Micrometastasis in the sentinel lymph node of breast cancer does not mandate completion axillary dissection. Ann Surg 2004; 239:859–65PubMedCrossRef

30.

Cserni G, Gregori D, Bussolati, et al. Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. Br J Surg 2004; 91:1245–52

31.

Cox C, Vrcel V, Riker A, et al. Significance of sentinel lymph node micrometastasis on survival for patients with invasive breast cancer. Breast Cancer Res Treat 2005; 94:S21

32.

American College of Surgeons Oncology Group. Giuliano A. A randomized trial of axillary node dissection in women with clinical T1 or T2 N0 M0 breast cancer who have a positive sentinel node. ACOZOG-Z0011. 2004. Available at: http://www.acosog.org/studies/organ_site/breast/index.jsp. Accessed January 16, 2006

33.

National Cancer Institute, US National Institutes of Health. Clinical trials. International Breast Cancer Study Group (IBCSG). Galimberti V. Trial 23-01. Phase III randomized study of surgical resection with or without axillary lymph node dissection in women with clinically node-negative breast cancer with sentinel node micrometastasis. 2004. Available at: http://www.cancer.gov/clinicaltrials/IBCSG-23-01. Accessed January 16, 2006

34.

Mansel R. AMAROS after mapping of the axilla: radiotherapy or surgery. EORTC 10981-22023. Available at: http://www.ncrn.org.uk/portfolio/data.asp?ID=1424. Accessed January 16, 2006

35.

Salmon RJ, Marcolet A, Vieira M, Languille O. Sentinel node biopsy or limited oriented axillary dissection in early breast cancer. Eur J Surg Oncol 2005; 31(9):949–53PubMedCrossRef

36.

Specht MC, Kattan MW, Van Zee, et al. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinician versus nomogram. Ann Sur Oncol 2005; 12:1–6

Title: Validation and Limitations of Use of a Breast Cancer Nomogram Predicting the Likelihood of Non–Sentinel Node Involvement After Positive Sentinel Node Biopsy
Authors: Séverine Alran, MD
Yann De Rycke, PhD
Virginie Fourchotte, MD
Hélène Charitansky, MD
Fatima Laki, MD
Marie Christine Falcou, DM
Myriam Benamor, MD
Paul Freneaux, MD
Rémy Jacques Salmon, MD
Brigitte Sigal-Zafrani, MD
for the Institut Curie Breast Cancer Study Group
Publication date: 01-08-2007
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 8/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-006-9331-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Validation and Limitations of Use of a Breast Cancer Nomogram Predicting the Likelihood of Non–Sentinel Node Involvement After Positive Sentinel Node Biopsy

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2007

Photodynamic Therapy with Curative Intent for Barrett’s Esophagus with High Grade Dysplasia and Superficial Esophageal Cancer

Comparing Surgical Outcomes in Obese Women Undergoing Laparotomy, Laparoscopy, or Laparotomy With Panniculectomy for the Staging of Uterine Malignancy

Heme Oxygenase-1 Gene Promoter Polymorphism is Associated with Risk of Gastric Adenocarcinoma and Lymphovascular Tumor Invasion

Analysis of Prognostic Factors Affecting Survival After Initial Recurrence and Treatment Efficacy for Recurrence in Patients Undergoing Potentially Curative Hepatectomy for Hepatocellular Carcinoma

Reoperative Sentinel Lymph Node Biopsy: A New Frontier in the Management of Ipsilateral Breast Tumor Recurrence

Prognostic Factors in Primary Gastric Lymphoma